JoVE Logo

Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

The current article describes the generation and metabolic characterization of high-fat diet-fed mice as a model of diet-induced insulin resistance and obesity. It further features detailed protocols to perform the oral glucose tolerance test and the insulin tolerance test, monitoring whole-body alterations of glucose metabolism in vivo.

Abstract

Obesity represents the most important single risk factor in the pathogenesis of type 2 diabetes, a disease which is characterized by a resistance to insulin-stimulated glucose uptake and a gross decompensation of systemic glucose metabolism. Despite considerable progress in the understanding of glucose metabolism, the molecular mechanisms of its regulation in health and disease remain under-investigated, while novel approaches to prevent and treat diabetes are urgently needed. Diet derived glucose stimulates the pancreatic secretion of insulin, which serves as the principal regulator of cellular anabolic processes during the fed-state and thus balances blood glucose levels to maintain systemic energy status. Chronic overfeeding triggers meta-inflammation, which leads to alterations in peripheral insulin receptor-associated signaling and thus reduces the sensitivity to insulin-mediated glucose disposal. These events ultimately result in elevated fasting glucose and insulin levels as well as a reduction in glucose tolerance, which in turn serve as important indicators of insulin resistance. Here, we present a protocol for the generation and metabolic characterization of high-fat diet (HFD)-fed mice as a frequently used model of diet-induced insulin resistance. We illustrate in detail the oral glucose tolerance test (OGTT), which monitors the peripheral disposal of an orally administered glucose load and insulin secretion over time. Additionally, we present a protocol for the insulin tolerance test (ITT) to monitor whole-body insulin action. Together, these methods and their downstream applications represent powerful tools to characterize the general metabolic phenotype of mice as well as to specifically assess alterations in glucose metabolism. They may be especially useful in the broad research field of insulin resistance, diabetes and obesity to provide a better understanding of pathogenesis as well as to test the effects of therapeutic interventions.

Introduction

In the developed world, obesity and diabetes reached epidemic dimensions due to physical inactivity and the excess consumption of processed food, effects which are driven by rapid urbanization, industrialization as well as globalization. Although research on insulin resistance and it's co-morbidities, such as hyperlipidemia and atherosclerosis, has gained prominence during the last decades, the complex biological mechanisms which regulate metabolism in health and disease remain incompletely understood and there is still an urgent need for new treatment modalities to prevent and treat these diseases1.

Insulin, and it's counter-regulatory hormone glucagon serve as the principal regulators of cellular energy supply and macronutrient balance, thus also maintaining proper systemic blood glucose concentrations2. Glucose itself acts as one of the main stimulators of insulin secretion by pancreatic β-cells, while other macronutrients, humoral factors as well as neural input further modify this response. Insulin consequently triggers the anabolic processes of the fed state by facilitating the diffusion of excess blood glucose into muscle and fat cells and further activating glycolysis as well as protein- or fatty acid synthesis, respectively. Additionally, insulin suppresses hepatic glucose output by inhibiting gluconeogenesis. Chronic excess energy consumption and meta-inflammation lead to hyperinsulinemia and peripheral insulin resistance due to the down-regulation of insulin receptor expression as well as alterations in downstream signaling pathways, thus resulting in impaired sensitivity to insulin-mediated glucose disposal as well as insufficient inhibition of hepatic glucose production3,4,5,6.

A wide range of animal models with genetic, nutritional, or experimental induction of disease have been proven to be excellent tools to study the molecular mechanisms of insulin resistance and various forms of diabetes as well as its accompanying illnesses7. A prime example is the widely used and well established HFD-induced mouse model, which is characterized by rapid weight gain due to increased dietary intake in combination with reduced metabolic efficiency, resulting in insulin resistance8,9. Both in animal models and humans, an elevation in fasting blood glucose and insulin levels, as well as an impaired tolerance to glucose administration are frequently used indicators of insulin resistance and other systemic alterations of glucose metabolism. Monitoring blood glucose and insulin levels at the basal state or after stimulation are therefore easily accessible readouts.

The present protocol outlines the generation of HFD-fed mice as well as two frequently used methods, the oral glucose tolerance test (OGTT) and the insulin resistance test (ITT), which are useful to characterize the metabolic phenotype and to investigate alterations in glucose metabolism. We describe the OGTT in detail, which assesses the disposal of an orally administered glucose load and insulin secretion over time. Further, we provide instructions on how to conduct the ITT to investigate whole-body insulin-action by monitoring blood glucose concentration in response to a bolus of insulin. The protocols described in this article are well-established and have been used in multiple studies10,11,12. In addition to slight modifications which may help to increase success, we provide guidelines for experimental design and data analysis, as well as useful hints to avoid potential pitfalls. The protocols described herein can be very powerful tools to investigate the influence of genetic, pharmacological, dietary, and other environmental factors on whole body glucose metabolism and on its associated disorders such as insulin resistance. In addition to stimulation with glucose or insulin, a variety of other compounds may be used for stimulation depending on the purpose of individual research. Although outside of the scope of this manuscript, many other downstream applications can be performed on the drawn blood samples, such as the analysis of blood values other than glucose and insulin (e.g., lipid and lipoprotein profiles) as well as detailed analysis of metabolic markers (e.g., by quantitative real time Polymerase Chain Reaction (PCR), Western blot analysis, and Enzyme-Linked Immunosorbent Assay (ELISA)). Further flow cytometry and Fluorescence Activated Cell Sorting (FACS) may be applied to investigate the effects in distinct single cell populations, while transcriptomic, proteomic, and metabolomic approaches may also be utilized for untargeted analysis.

Overall, we provide a simple protocol to generate an HFD-induced mouse model, while further describing two powerful approaches to study whole-body metabolic alterations, the OGTT and the ITT, which can be useful tools for studying disease pathogenesis and developing new therapies, especially in the field of metabolism-associated diseases such as insulin resistance & diabetes.

Protocol

All methods described here have been approved by the Animal Care and Use Committee of the Medical University of Vienna and conducted according to the Federation of European Laboratory Animal Science Associations (FELASA). Please note that all procedures described in this protocol should only be performed after institutional and governmental approval as well as by staff that are technically proficient.

1. HFD-fed mice

NOTE: Maintain all C57BL/6J mice on a 12-h light/dark cycle with free access to food and water.

  1. At 6 weeks of age, place mice for 8-12 weeks on an HFD (40-60% fat calories) to induce obesity, while feeding the lean control-group a low-fat diet (LFD) (10% fat calories).
  2. Determine the body weight of the mice on a weekly basis. The weight curves should show similar patterns in both groups, with a higher slope in the HFD-fed group.

2. OGTT

NOTE: If blood sampling time points are chosen during OGTT every 15 min, the experiment should be performed with a maximum of 15 mice in parallel, in order to have at least 1 min handling-time per mouse.

  1. Preparations on the day before OGTT
    1. Transfer the mice into a cage with fresh bedding and fast them overnight before testing (14 h), while ensuring that the mice have access to drinking water (e.g., remove the food at 6:00 pm for a start time on the next morning at 8:00 am).
      NOTE: Fasting mice overnight is the standard approach, however a shorter fast (5-6 h) is more physiological for mice (see Discussion for details).
  2. Preparations on the day of the experiment (but prior to the experiment)
    1. Prepare 10 mL of 20% glucose solution (dissolve D-(+)-Glucose in distilled water).
      NOTE: All reagents that are administered to the animals have to be pharmacological grade and sterile.
    2. Prepare a 96-well plate for plasma collection, by filling one well for each sampling time point and each mouse, with 5 µL NaEDTA (0.5 M EDTA, pH 8.0 in 0.9% NaCl, storage at RT). During the experiment, store this plate on ice.
      NOTE: See Supplementary Figure 1 for a detailed checklist.
  3. Measure the body weight of all mice and mark their tails with a permanent marker in order to make the mice easily distinguishable (e.g., mouse 1 = 1 dash, mouse 2 = 2 dashes, etc.).
  4. Glucose measurement and blood sampling (Figure 2)
    1. Carefully cut off 1-2 mm of the tail tip using sharp scissors ("Variant A" in Figure 2). Always wipe off the first drop of blood to avoid hemolysis or contamination with tissue fluid before taking new blood samples for blood glucose determination. Draw a small blood sample (~3 µL) for the measurement of the basal blood glucose level (= time point 0) with the glucometer.
      CAUTION: Check and adjust the charge number of test strips on a glucometer.
      NOTE: As an alternative blood sampling method, nick the lateral tail vein of a mouse with a sharp scalpel blade ("Variant B" in Figure 2). The lateral tail vein is usually accessed approximately one-third along the length of the tail from the tail tip, moving towards the base of the tail for multiple samples. The use of a local anesthetic cream is recommended. Stop blood flow by applying finger pressure on the soft tissue for at least 30 s before the animal is returned to its cage.
    2. Collect a blood sample (around 30 µL) using a fresh capillary tube (keep the capillary tube horizontal). Empty the capillary tube using a pipette by putting the pipette tip at the top of the capillary tube end and carefully pushing the collected blood into a well of the 96-well plate, while avoiding air bubbles. Repeat this procedure for all mice - one at a time.
      NOTE: As an alternative for blood collection via a capillary tube, use a pipette adjusted to the correct volume (e.g., 30 µL) to collect blood, or collect a drop of blood from the tail on paraffin film, and pipet it into the EDTA-solution. Strictly avoid the contact of petroleum jelly with blood or glucometer test strips, as it may influence subsequent glucose and insulin measurements.
      CAUTION: The OGTT is very stressful for mice: lean mice can lose around 15% of their body weight during an overnight fast. Additionally, blood sampling at different time points leads to a considerable loss of blood. For easier blood sampling, it is possible to carefully massage the mouse-tail with petroleum jelly.
      NOTE: Institutional guidelines may limit the allowable amount of blood collected within a set period. The sampling volumes and timepoints should be adjusted to not exceed the allowed maximums. The body weight of the mice should be used to calculate the total blood withdrawal permitted.
  5. Calculate the required volume of glucose solution based on body weight (1 g glucose/kg body weight; this can be increased up to 3 g/kg) to be administered by oral gavage for every mouse. For example, a mouse with a body weight of 30 g would need 150 µL of a 20% glucose solution to administer 30 mg of glucose.
    NOTE: To base the dose of glucose on the weight of the mouse is the standard procedure. If body composition data are available, the dose of glucose for OGTT should be calculated based on the lean body mass (see Discussion for details).
  6. Glucose administration
    1. Prepare everythingthat is needed during the whole experiment in advance (timer, experiment record sheet, glucose monitor and strips, capillaries, syringes, glucose solution, 96-well plate, scalpel, calculator, balance, permanent marker, bench papers, a pipette with a tip, and gloves).
    2. For glucose application, restrain the mouse by firmly grasping it by the scruff. Apply enough firmness to the skin around the neck to prevent the mouse from twisting out of the restrain and to properly tilt its head back. Also ensure that the mouse can breathe properly.
      NOTE: Once glucose administration is started, good time management is very important.
    3. Carefully administer the glucose solution (based on step 2.5) directly into the stomach using a feeding needle. Cautiously direct the feeding needle through the mouth towards the esophagus. Allow the mouse to swallow the needle: the needle entirely sinks into the lower esophagus/stomach of the mouse. Then inject the glucose solution (Figure 3a).
      1. If any resistance is met or if the animal struggles immediately, withdraw the needle and reposition it.Start the timer immediately after the first gavage and administer glucose to all other mice in 1 min intervals.
        NOTE: It may be helpful to apply a drop of glucose solution directly from the feeding needle to the mouth of the mouse, which will stimulate licking and swallowing, thus facilitating easier insertion of the feeding needle. Do not apply pressure when inserting the feeding needle as this may seriously injure the animal.
  7. After 15 min, measure blood glucose levels with the glucometer and additionally take blood samples (~30 µL) (as described in detail in step 2.4) of each mouse in the same order as they were injected.
    NOTE: The time management is very important; follow as closely as possible using the same time intervals as for gavage. Let the mice move as freely as possible and limit restraining to a minimum during the whole procedure to reduce stress, which may modify the results. Milk tail with one hand and collect the blood with the other.
  8. Repeat step 2.7 at selected time points depending on the expected results (e.g., at 30, 45, 60, 90, 120, 150, and 180 min after glucose administration). If the selected time points are longer than 120 min, ensure that the mice have access to drinking water. Ensure that the mice have always access to drinking water. When finished with the experiment, return the mice to their home cages equipped with food and water.
    CAUTION: The OGTT is very exhausting for the mice. Therefore wait at least 1 week before performing the next metabolic test, such as an ITT.
  9. After the experiment, centrifuge blood samples at 2,500 x g, 30 min, 4 °C. Transfer the supernatant (plasma) to empty wells of the plate and store it at -20 °C until analysis.
    1. Record hemolysis of samples if present (see Section 3).
  10. Determine plasma insulin levels using a commercially available ELISA kit (see the Table of Materials) following the manufacturer's instructions of the kit.
    NOTE: Depending on the fasting state as well as on the metabolism of the investigated mice, difficulties during this assay may occur: overnight fasting insulin levels (time point 0) are very low and therefore close to the detection limit. To avoid this issue, double the quantity of recommended plasma volume and accordingly halve the result of the ELISA assay. On the other hand, if mice reach the insulin peak during OGTT, especially in HFD-fed mice, the insulin levels may exceed the detection limit: dilute the sample (e.g., 10-fold with 0.9% NaCl) and repeat the ELISA assay. Hemolysis in plasma samples may lead to the degradation of insulin, resulting in a decrease of the readout values. The degradation depends on time, temperature, and the hemoglobin concentration in the sample. Always keep hemolyzed samples cold or on ice to reduce insulin degradation.

3. ITT

NOTE: The same precautions described for OGTT (handling of mice, blood, glucometer, and petroleum jelly use) also have to be applied when performing the ITT. For example, all injections should be carried out within 15 min in 1 min intervals if 15 mice are tested in parallel. For the ITT, subsequent collection of blood samples with capillary tubes is optional.

  1. Preparations before the experiment
    1. Fast mice for at least 2 h before insulin injection, while ensuring that the mice have access to drinking water (e.g., remove food at 8:00 am, test mice 2-5 h later).
    2. Dilute insulin 1:1,000 in 0.9% NaCl (Stock: 100 U/mL insulin; working concentration 0.1 U/mL) and prepare 20% glucose (D-(+)-Glucose solution dissolved in distilled water) to be administered if the mice become hypoglycemic.
      NOTE: The ITT is typically performed after a short fast to avoid the hypoglycemia which may otherwise occur in overnight fasted animals. All reagents that are administered to the animals have to be pharmacological grade and sterile.
  2. Measure the bodyweight of mice, mark tail, cut the tail tip using sharp scissors, and measure basal blood glucose levels as described previously for the OGTT in step 2.4.
  3. Insulin injection
    1. To inject insulin intraperitoneally (0.75 U insulin/kg body weight, calculated beforehand), restrain the mouse by the scruff method.
    2. Use a fresh, sterile 27 or 30 gauge needle for each animal to avoid discomfort and the risk of any injection-site infection.
      NOTE: Sterilization of the skin can prolong the duration of insulin administration, and thus can cause additional disturbances to the animal. Therefore, it is not recommended.
    3. Tilt the mouse head down at a slight angle to expose the ventral side of the animal. Place the sterile needle with the bevel up and at a 30 ° angle in the lower right quadrant of the animal's abdomen (Figure 3b). Start the timer immediately after the first mouse is injected.
      NOTE: Low-dose ITTs (0.1 U/kg) may be performed to specifically assess hepatic insulin sensitivity. As for the OGTT, calculating the injection volume based on body weight is the standard procedure, while basing the dose on lean body mass is preferred if body composition data are available.
  4. Measure blood glucose levels at selected time points (e.g., after 15, 30, 45, 60, and 90 min).
    NOTE: As insulin has a short half-time of ~10 min in mice13, late differences after insulin administration (e.g., after 2 h) may not reflect a direct effect of insulin action. Administer 20% glucose solution in case a mouse becomes hypoglycemic (blood glucose levels below 35 mg/dL) and is in risk of dying.
  5. After the final time points, place the mice back into their home cages prepared with plenty of food and water.

Results

Figure 1 illustrates a schematic time table for metabolic phenotyping of mice on diets. At an age of approximately 6 weeks, mice should be placed on an HFD, while an LFD-group may serve as the control group. Importantly, body weight should be determined weekly to observe if there is an expected increase in body weight. Any kind of stress (e.g., noise or aggressive male behavior) can interfere with body weight gain and should be eliminated immediately...

Discussion

With the high prevalence of diabetes and associated diseases in the world's population, there is a strong requirement for research addressing the molecular mechanism, prevention, and treatment of disease19. The presented protocol describes well-established methods for the generation of HFD mice, a robust animal model used for metabolic research, as well as the conduction of the OGTT and ITT, which are potent tools for the assessment of whole-body metabolic alterations such as insulin resistanc...

Disclosures

The authors have nothing to disclose.

Acknowledgements

This research was supported by the Medical Scientific Fund of the Mayor of the City of Vienna and the Österreichische Gesellschaft für Laboratoriumsmedizin und Klinische Chemie.

Materials

NameCompanyCatalog NumberComments
Mouse strain: C57BL/6JThe Jackson Laboratory664LFD/HFD
Accu Chek Performa - GlucometerRoche6870228OGTT/ITT
Accu Chek Performa - StripsRoche6454038OGTT/ITT
D-(+)-Glucose solutionSigma-AldrichG8769OGTT
Actrapid - InsulinNovo Nordisk417642ITT
Reusable Feeding NeedlesFine Science Tools#18061-22OGTT; 22 gauge (-24 gauge for young mice)
Omnifix-Fine dosing syringesBraun9161406VOGTT/ITT
Sterican Insulin needle (30G x 1/3"; ø 0.30 x 13 mm)Braun304000ITT; lean mice
Sterican (G 27 x 3/4"; ø 0.40 x 20 mm)  Braun4657705ITT; mice on HFD
96 Well PCR Plates, non-skirted, flexibleBraintree Scientific, Inc.SP0016OGTT
Ultrasensitive Mouse Insulin ELISA kitCrystam Chem90080OGTT
Rodent Diet with 60% kcal% fatResearch Diets IncD12492mice on HFD
Rodent Diet with 10% kcal% fat.Research Diets IncD12450Bmice on LFD
BRAND micro haematocrit capillarySigma-AldrichBR749321OGTT/ITT
Vaseline - cremeRivieraP1768677OGTT/ITT

References

  1. Qatanani, M., Lazar, M. A. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 21 (12), 1443-1455 (2007).
  2. Wilcox, G. Insulin and insulin resistance. Clin Biochem Rev. 26 (2), 19-39 (2005).
  3. Reaven, G. M. Pathophysiology of insulin resistance in human disease. Physiol Rev. 75 (3), 473-486 (1995).
  4. Kahn, B. B. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell. 92 (5), 593-596 (1998).
  5. Gregor, M. F., Hotamisligil, G. S. Inflammatory mechanisms in obesity. Annu Rev Immunol. 29, 415-445 (2011).
  6. Odegaard, J. I., Chawla, A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science. 339 (6116), 172-177 (2013).
  7. Srinivasan, K., Ramarao, P. Animal models in type 2 diabetes research: an overview. Indian J Med Res. 125 (3), 451-472 (2007).
  8. Surwit, R. S., Kuhn, C. M., Cochrane, C., McCubbin, J. A., Feinglos, M. N. Diet-induced type II diabetes in C57BL/6J mice. Diabetes. 37 (9), 1163-1167 (1988).
  9. Winzell, M. S., Ahren, B. The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes. 53, S215-S219 (2004).
  10. Ayala, J. E., et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 3 (9-10), 525-534 (2010).
  11. Jais, A., et al. Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and man. Cell. 158 (1), 25-40 (2014).
  12. Teperino, R., et al. Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. Cell. 151 (2), 414-426 (2012).
  13. Cresto, J. C., et al. Half life of injected 125I-insulin in control and ob/ob mice. Acta Physiol Lat Am. 27 (1), 7-15 (1977).
  14. First report of the BVA/FRAME/RSPCA/UFAW joint working group on refinement. Removal of blood from laboratory mammals and birds. Lab Anim. 27 (1), 1-22 (1993).
  15. McGuill, M., Rowan, A. Biological Effects of Blood Loss: Implications for Sampling Volumes and Techniques. ILAR. 31 (4), 5-18 (1989).
  16. Hoff, J. Methods of Blood Collection in the Mouse. Lab Animal. 29 (10), 47-53 (2000).
  17. Jacobson, L., Ansari, T., McGuinness, O. P. Counterregulatory deficits occur within 24 h of a single hypoglycemic episode in conscious, unrestrained, chronically cannulated mice. Am J Physiol Endocrinol Metab. 290 (4), E678-E684 (2006).
  18. Guariguata, L., et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 103 (2), 137-149 (2014).
  19. Freeman, H. C., Hugill, A., Dear, N. T., Ashcroft, F. M., Cox, R. D. Deletion of nicotinamide nucleotide transhydrogenase: a new quantitive trait locus accounting for glucose intolerance in C57BL/6J mice. Diabetes. 55 (7), 2153-2156 (2006).
  20. Pelleymounter, M. A., et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 269 (5223), 540-543 (1995).
  21. Chen, H., et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 84 (3), 491-495 (1996).
  22. Rossini, A. A., Like, A. A., Dulin, W. E., Cahill, G. F. Pancreatic beta cell toxicity by streptozotocin anomers. Diabetes. 26 (12), 1120-1124 (1977).
  23. Bailey, C. J., Flatt, P. R. Hormonal control of glucose homeostasis during development and ageing in mice. Metabolism. 31 (3), 238-246 (1982).
  24. Shi, H., et al. Sexually different actions of leptin in proopiomelanocortin neurons to regulate glucose homeostasis. Am J Physiol Endocrinol Metab. 294 (3), E630-E639 (2008).
  25. Collins, S., Martin, T. L., Surwit, R. S., Robidoux, J. Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav. 81 (2), 243-248 (2004).
  26. Heijboer, A. C., et al. Sixteen hours of fasting differentially affects hepatic and muscle insulin sensitivity in mice. J Lipid Res. 46 (3), 582-588 (2005).
  27. Kohsaka, A., Bass, J. A sense of time: how molecular clocks organize metabolism. Trends Endocrinol Metab. 18 (1), 4-11 (2007).
  28. Drucker, D. J. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 62 (10), 3316-3323 (2013).
  29. Andrikopoulos, S., Blair, A. R., Deluca, N., Fam, B. C., Proietto, J. Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab. 295 (6), E1323-E1332 (2008).
  30. Ahren, B., Winzell, M. S., Pacini, G. The augmenting effect on insulin secretion by oral versus intravenous glucose is exaggerated by high-fat diet in mice. J Endocrinol. 197 (1), 181-187 (2008).
  31. Bowe, J. E., et al. Metabolic phenotyping guidelines: assessing glucose homeostasis in rodent models. J Endocrinol. 222 (3), G13-G25 (2014).
  32. Arioli, V., Rossi, E. Errors related to different techniques of intraperitoneal injection in mice. Appl Microbiol. 19 (4), 704-705 (1970).
  33. Miner, N. A., Koehler, J., Greenaway, L. Intraperitoneal injection of mice. Appl Microbiol. 17 (2), 250-251 (1969).
  34. Heikkinen, S., Argmann, C. A., Champy, M. F., Auwerx, J. Evaluation of glucose homeostasis. Curr Protoc Mol Biol. Chapter. , 23 (2007).
  35. Muniyappa, R., Lee, S., Chen, H., Quon, M. J. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 294 (1), E15-E26 (2008).
  36. McGuinness, O. P., Ayala, J. E., Laughlin, M. R., Wasserman, D. H. NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse. Am J Physiol Endocrinol Metab. 297 (4), E849-E855 (2009).
  37. Pacini, G., Omar, B., Ahren, B. Methods and models for metabolic assessment in mice. J Diabetes Res. 2013, 986906 (2013).
  38. Polonsky, K. S., Rubenstein, A. H. C-peptide as a measure of the secretion and hepatic extraction of insulin. Pitfalls and limitations. Diabetes. 33 (5), 486-494 (1984).
  39. Hughey, C. C., Wasserman, D. H., Lee-Young, R. S., Lantier, L. Approach to assessing determinants of glucose homeostasis in the conscious mouse. Mamm Genome. 25 (9-10), 522-538 (2014).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

In Vivo Glucose MetabolismHigh fat DietMiceOral Glucose Tolerance Test OGTTInsulin Tolerance Test ITTMetabolic PhenotypeGlucose MetabolismGenetic FactorsPharmacological FactorsDietary FactorsBody WeightBlood GlucoseGlucose SolutionGlucose AdministrationGavage

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved